ArticleCellular oncology (Dordrecht, Netherlands)2013
Chromosome 1q25.3 copy number alterations in primary breast cancers detected by multiplex ligation-dependent probe amplification and allelic imbalance assays and its comparison with fluorescent in situ hybridization assays.
Article in Cellular oncology (Dordrecht, Netherlands), 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 9 citations in OpenAlex.
- QSOX1: A Mysterious Golgi-Localized Disulfide Bond Catalyst and an Emerging Cancer Regulator.Cancers · 2026Article
- COLGALT2 is overexpressed in ovarian cancer and interacts with PLOD3.Clinical and translational medicine · 2021Article
- The toxicity and therapeutic effects of single-and multi-wall carbon nanotubes on mice breast cancer.Scientific reports · 2018Article
- Prognostic and predictive value of copy number alterations in invasive breast cancer as determined by multiplex ligation-dependent probe amplification.Cellular oncology (Dordrecht, Netherlands) · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBreast cancer is characterized by a complex pattern of chromosomal alterations, which is in accordance with its heterogeneous character. Simultaneous gains of 1q and losses of 16q represent early events in breast tumourigenesis and have been related to clinical outcome. Here, we evaluated the accuracy of 1q25.3 copy number detection in conjunction with allelic imbalance (AI) detection in a series of primary breast tumours.
methodsWe compared previously obtained AI results from the 1q25.3 region in a series of 222 primary breast tumours with newly obtained MLPA and FISH results. To this end, a novel 1q25.3 MLPA probe set was designed and a commercially available 1q25.3/1p35.2 dual color FISH probe set was used.
resultsMLPA revealed 1q25.3 copy number gains and copy number losses in subsets of the tumour samples tested. Next, tumour samples were examined by FISH and scored for the level of 1q25.3 alterations. Non-tumourigenic nuclei from healthy individuals were used to establish cut-off levels for 1q25.3 copy numbers. By doing so, we found a 100 % concordance between the FISH results in breast tumour samples displaying similar 1q25.3 copy number alterations as determined by MLPA and, previously, AI. Furthermore, FISH was found to be instrumental in determining 1q25.3 copy number alterations in samples exhibiting discordances between AI and MLPA.
conclusionsThis study shows that both AI and MLPA assays can be employed to map regions exhibiting copy number alterations in cancer genomes, and that the results obtained are in concordance with FISH assays.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.